Novel sulfanone derivative or pharmaceutically acceptable salt thereof, and use thereof

A pharmaceutical composition for preventing or treating one or more disease selected from a group consisting of liver disease, kidney disease, pulmonary disease, neurodegenerative disease, mitochondrial myopathy, Friedreich's ataxia, corneal endothelial cell loss and psoriasis, comprising a sulfanone derivative represented by the following [Chemical Formula 1] or a pharmaceutically acceptable salt thereof as an active ingredient:

• In Chemical Formula 1,
• A and B are each independently phenyl or pyridine;
• R is hydrogen, a cyano group, a trimethylsilyl group (Trimethylsilane, TMS), or a methyl group (except when the A and B are both phenyl, and when R is hydrogen);
• wherein each of the A and B is unsubstituted or substituted with any one or more substituents selected from a group consisting of a hydroxy group, a halogen group, a cyano group, a nitro group, a C1-C7 alkyl group, and a C1-C7 alkoxy group (except when the A and B are both unsubstituted);
• and
• wherein one or more hydrogen of the alkyl group or alkoxy group are unsubstituted or substituted with any one or more substituent selected from a group consisting of a hydroxy group, a cyano group, a nitro group, and a morpholine group.

A method for preparing a sulfanone derivative or a pharmaceutically acceptable salt thereof, the method comprising the following steps:

• (1) preparing a compound represented by [Chemical Formula 3] from a compound represented by [Chemical Formula 2];
• (2) preparing a compound represented by [Chemical Formula 4] from the compound represented by [Chemical Formula 3];
• (3) preparing a compound represented by [Chemical Formula 5] from the compound represented by [Chemical Formula 4];
• and
• (4) preparing a compound represented by [Chemical Formula 1] by adding a compound represented by [Chemical Formula 6] to the compound represented by [Chemical Formula 5].
• in Chemical Formulae 1 to 6,
• A and B are each independently phenyl or pyridine (except when the A and B are both phenyl);
• R is hydrogen, a trimethylsilyl group (Trimethylsilane, TMS), or a methyl group;
• wherein each of the A and B is unsubstituted or substituted with any one or more substituents selected from a group consisting of a hydroxy group, a halogen group, a cyano group, a nitro group, a C1-C7 alkyl group, and a C1-C7 alkoxy group (except when the A and B are both unsubstituted);
• and
• wherein one or more hydrogen of the alkyl group or alkoxy group are unsubstituted or substituted with any one or more substituent selected from a group consisting of a hydroxy group, a cyano group, a nitro group, and a morpholine group.